ABVCHealthcare · BiotechnologyABVC Stock Forecast: ABVC BioPharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 12 Sept 2026 — in the weakest quartile.
ABVC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ABVC BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ABVC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ABVC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2022 | Maxim Group | Downgrade | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABVC appears on the weeks it earns a place.
ABVC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, ABVC BioPharma, Inc. returned −64.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ABVC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ABVC BioPharma, Inc. (ABVC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 2.4×
- EV / EBITDA
- −4.7×
Cheaper than 74% of US stocks
Cheaper than 39% of US stocks
Cheaper than 78% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −69.9%
- Return on assets
- −22.9%
- Dividend yield
- —
Higher than 17% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ABVC BioPharma, Inc. (ABVC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ABVC BioPharma, Inc. has a market value of $26.1M and an enterprise value of $30.2M.
Revenue in the twelve months to 30 June 2026: −$796K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$8.4M, a 1054.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$3.5M.
Trailing P/E: 0.0×; forward P/E: −2.2× — the forward figure prices analyst consensus estimates, not reported earnings.
ABVC BioPharma, Inc. employs 16 people — −$50K of revenue per employee.
Data provided by Twelve Data
ABVC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ABVC BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ABVC stock
How does Ticker Nerd's model rank ABVC?
As at 12 Sept 2026, ABVC BioPharma, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
What is the ABVC stock forecast for 2030?
No analyst covering ABVC BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABVC are extrapolating price history, which says nothing about the business.
How has ABVC stock performed over the past year?
ABVC BioPharma, Inc. returned -64.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ABVC BioPharma, Inc. do?
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing new drugs and medical devices derived from plants.
About ABVC BioPharma, Inc.
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing new drugs and medical devices derived from plants. The company works across therapeutic areas including central nervous system disorders, oncology, hematology, and ophthalmology, using botanical science and licensed research to advance candidates through early and mid-stage clinical development. Its current portfolio includes multiple drug programs and medical devices designed to address unmet medical needs, with an emphasis on proof-of-concept studies and collaborative development. ABVC Biopharma also operates an asset-light model that relies on licensing, partnerships, and clinical trial execution to move products toward commercialization. Headquartered in Fremont, California, ABVC Biopharma serves as a specialized participant in the broader biotechnology market, combining plant-based innovation with drug and device development.
CEO Dr. Uttam Yashwant Patil Ph.D. · 16 employees · United States · https://www.abvcpharma.com